The State of the Pharmaceutical Royalty Market, May 2026

For most of its history the pharmaceutical royalty market was a quiet corner of structured finance. A handful of specialist funds bought claims on the future sales of approved drugs, collected the cash flows, and raised the next fund. The asset class worked precisely because it was unglamorous and uncrowded.

That description no longer fits. May 2026 is a good moment to take stock, because the market has changed shape on almost every axis at once. Volume hit a record in 2025. The buying side has filled up with capital that was not there three years ago. A whole new supply of assets is coming out of China. And the dedicated aggregators, the firms that defined the market, are consolidating fast.

This piece is an attempt to map the whole thing as it stands: how big the market actually is and how the volume breaks down, who is buying and who is selling, where in the world the assets and the capital sit, and what is happening to the aggregators in the middle. The consolidation story is the sharpest single development, so it gets its own section, but it is one part of a wider picture rather than the whole of it.

How big the market is, and what the volume is made of

Start with size, because the headline number is both real and slightly slippery.

Royalty Pharma's full-year 2025 results, reported in February 2026, put announced transactions at $4.7 billion of total potential value, on $2.6 billion of cash deployed, with Portfolio Receipts up 16% to $3,254 million. Its January 2026 J.P. Morgan presentation sized the announced market at roughly $10 billion in 2025, about 40% above the $7.1 billion-a-year average of the prior five years. That is the largest number in circulation, and it comes from the largest participant, so it bundles milestones, term loans, and revenue-interest structures alongside true royalty acquisitions.

A narrower count tells a calmer story. Gibson Dunn's deal tracker, which captures only publicly disclosed transactions with enough detail to characterise, records $7.1 billion in 2025 across 25 to 27 deals at a median single-deal size of around $221 million, and more than $32 billion cumulatively across 133 transactions since 2020. Goodwin's parallel work put roughly $29.4 billion of financings from 2020 through 2024, more than double the prior five years.

The two measures disagree on the level but agree on the direction. The market is two to three times the size it was a decade ago, and 2025 was a record on both. I worked the deal-level detail of the recent cohort through in the H1 2025 global analysis.

What the volume is made of matters more than the exact total. Three shifts stand out.

The first is that synthetic royalties have become the workhorse structure. A synthetic royalty is created fresh on the future sales of a drug the seller still owns, rather than bought from someone who already holds an existing royalty. Gibson Dunn's tracking shows synthetics moving from roughly half the market early in the decade to the clear majority of deal value in 2024 and 2025. Royalty Pharma alone wrote $4.7 billion of synthetic deals in 2025 against a $925 million record the year before.

The second is that the deals are starting earlier. Pre-approval and development-stage financings are now a meaningful share of both count and value, structured with caps, milestones, and tranches that release cash on regulatory or sales triggers. The Denali synthetic on a PDUFA-stage asset and the development-stage tranche of the Revolution Medicines arrangement are the cleanest examples.

The third is concentration. Royalty Pharma's own framing puts its 2025 share near 40% of the market, and the top three or four buyers take the bulk of US deal value. That concentration is the backdrop to the consolidation story below, and it is getting tighter, not looser.

The honest caveat on all of this is that there is no loan-tape equivalent for royalties. Every market-size figure is an estimate built on disclosed deals, and disclosure is incomplete, so the totals should be read as direction rather than precision.

The buying side: capital is crowding in

The most important development of the last two years is on the demand side. The pool of buyers has widened well beyond the specialist funds and the Canadian and UK pensions that anchored the asset class in the late 2010s.

The largest new pool is insurance capital. The Apollo and Athene model, in which annuity liabilities fund long-duration, illiquid, cash-yielding assets, fits pharma royalties almost perfectly, because a royalty's multi-year cash flow matches an annuity book's payout profile better than most private credit. Apollo runs $938 billion of assets under management with a large perpetual-capital insurance base inside it, and KKR's Global Atlantic plays the same game, which is part of why KKR wanted a royalty origination engine of its own.

There is a regulatory shadow over this channel worth naming. US insurance capital treatment is set by the NAIC, which is mid-way through a multi-year tightening of how structured and asset-backed holdings are charged against capital. Royalties have mostly escaped the worst of that scrutiny so far because they tend to sit outside the bond chassis, but the capital treatment of royalty-backed notes is a live question for 2026 and 2027, and it bears directly on how much insurance money keeps flowing in.

Alongside insurance, the private credit and asset-based finance platforms have built explicit royalty capabilities. Apollo, Ares, Blue Owl, Brookfield, Blackstone, and Sixth Street all now market royalty financing as one slice of a broader asset-based finance strategy. Sixth Street is the cleanest template, having financed Biohaven, Blueprint, and Beam with a mix of convertible preferred, secured debt, and synthetic royalty in a single wrapper. Blackstone has executed at the largest scale, including a $700 million synthetic royalty with Merck on an oncology asset in late 2025 and the parallel $310 million sale of its Amvuttra royalty to Royalty Pharma in the same quarter.

Sovereign wealth is a smaller direct presence than its headline size suggests. GIC, ADIA, Mubadala, and their peers are deeply embedded as investors in the credit funds that buy royalties, but direct sovereign purchase of pharmaceutical royalties remains rare and mostly confined to co-investment alongside a lead manager. The exception is the Asian sovereign and corporate-pension capital anchoring the region's dedicated platform, which matters for the China story below.

Endowments, foundations, and family offices fill out the rest, generally as co-investors on $25 to $75 million tickets rather than as franchise buyers. Hedge funds appear opportunistically around forced sellers and restructurings rather than as durable holders.

The pension money that anchored the asset class is still arriving, and the case for it is now well documented. I went through it in full in Why Pension Funds Are Investing in Pharmaceutical Royalties, so the short version will do: CalSTRS has reported a 14.1% net IRR on its royalty fund commitment, correlations to equities and credit sit around 0.2 to 0.3, the duration matches a maturing pension's liability runoff, and total documented pension capital in the space is around $5.5 billion, still under 0.1% of global pension assets. The runway is long.

One pension behaviour matters specifically for market structure, because it makes the largest plans competitors rather than just clients. Some now originate directly. As I traced in the CPPIB profile, Canada's national plan holds Keytruda, venetoclax, and Leqvio royalties outright and has structured its own synthetic on BridgeBio's acoramidis, while OMERS runs its roughly $900 million Crysvita position directly. The reason this presses on the aggregators is the fee arithmetic: a pension investing directly pays operating cost only and nets close to its gross return, while an LP in a traditional fund gives up the better part of two-and-twenty. That gap is exactly what drove Royalty Pharma and DRI to internalise their managers, and it is what makes a direct-investing pension a genuine competitor for assets.

The selling side: supply is diversifying too

The supply of royalty assets has broadened in parallel with the demand, and the shift in who sells is as telling as the growth in who buys.

Biotech companies are still the largest source by deal count. The driver is non-dilutive launch capital: a synthetic royalty raises money against future sales without issuing equity at a depressed share price or taking on covenant-heavy debt. With biotech valuations soft for much of the period, equity issuance fatigue has been a steady tailwind, and the Cytokinetics, Blueprint, Biohaven, and Revolution Medicines deals are the canonical recent examples.

Academic institutions and research charities remain the original sellers, monetising legacy royalties to fund the next generation of research. The Cystic Fibrosis Foundation and LifeArc are the templates here, and I looked at the charity model in detail in the LifeArc profile. This is a low-volume, high-ticket channel, and it has slowed as the easiest legacy assets have already been sold.

The genuinely new seller is Big Pharma. The Merck and Blackstone synthetic in late 2025 is the clearest signal that the majors now use royalty structures for portfolio de-risking and balance-sheet optimisation rather than as a funding tool of last resort. The XOMA and Takeda arrangement, in which Takeda reduced its royalty and milestone obligations on one asset in exchange for XOMA taking rights across a basket of externalised Takeda programs, is the most structurally creative version of the same idea. When a cash-rich major sells a royalty, it is making a capital-allocation choice, not raising rescue money, and that is a different and more durable kind of supply.

Geography: where the assets are, where the capital is, and the China wave

The royalty market has always had a geographic mismatch, and a new one is opening up.

The United States dominates the origination of underlying assets because it dominates the origination of drugs. Roughly 72% of new regulatory filings come from biotechs, most of them US-domiciled or US-listed, and the synthetic-royalty mechanic was perfected in US capital markets. The structure is portable, and European counsel now executes it for French, German, Swiss, and Nordic biotechs, but European deal flow is still a fraction of the US figure.

Europe is structurally a net supplier of assets and a net importer of capital. European biotechs are increasingly comfortable selling future royalty streams, but the largest pools of European capital that buy them are concentrated in a few pensions, and there is still no European-domiciled Royalty Pharma equivalent buying at scale. The mismatch produces a persistent west-to-east-to-west flow: European assets, North American capital. I have argued before that the reasons are as much cultural and consultant-driven as regulatory, and they have not changed.

The frontier, and the freshest part of the whole market, is Asia, and specifically China.

The scale of the China shift is hard to overstate. Cross-border out-licensing from Greater China biotechs to Western pharma reached an announced $137.7 billion in 2025, up from $13.9 billion in 2021, and China-origin assets accounted for roughly a third of the industry's licensing spend in 2025, up from around a fifth in 2023 and 2024. More than two dozen China-origin deals crossed $1 billion in headline value in the first half of 2025 alone. The era of cheap Chinese assets is already closing: average upfronts have risen sharply as Western buyers compete.

The structural innovation that brings this into the royalty market is the NewCo model. Rather than license directly to a Western major, a Chinese biotech increasingly spins an asset into a Western-domiciled company backed by US and European venture investors, keeping an equity stake plus a milestone-and-royalty stream.

For a royalty buyer this is the important part: the NewCo generates a future, ex-China royalty that sits in a Delaware or European vehicle under familiar contract law, which is far cleaner to underwrite and to monetise than a royalty payable out of China. The NewCo is the bridge by which Asian innovation enters the royalty market without the legal and currency friction of a direct China-counterparty deal.

The marquee proof point already exists. In August 2025 Royalty Pharma agreed to pay BeOne Medicines, the renamed BeiGene, up to $950 million for its royalty on ex-China sales of Amgen's Imdelltra, a stream that originated in a 2019 BeiGene and Amgen collaboration. The royalty itself is on an Amgen product, but the seller is a Chinese-origin biotech, and the deal signals that the largest Western aggregator now treats Asian counterparties as core flow rather than an exception.

Royalty Pharma then made the commitment structural. In March 2026 it hired Kenneth Sun from Morgan Stanley as its Head of Asia, based in Hong Kong, the clearest written statement by any Western aggregator that China-origin flow is now a strategy rather than an opportunistic trade. Expect the first true China-origin synthetic royalty, as opposed to a royalty on a Western drug sold by a Chinese company, to be the regime-defining deal of the next year or two.

The one dedicated Asia-Pacific royalty platform at scale closed a $500 million fund in October 2025, the largest healthcare private-credit fund raised in the region, and its head of royalties has made the pitch explicitly: Western companies will sell their Asian royalty streams because the market chronically undervalues them. That is a description of a large future origination pipeline.

Two more Asian threads are worth watching. Korea added roughly $14.5 billion of out-licensing in 2025, nearly triple the prior year, anchored by large GSK and AstraZeneca deals and by Alteogen's subcutaneous-delivery platform royalties, though Korean royalty monetisation has not yet meaningfully reached Western buyers. And Japan's amended disclosure rules, which bite for the first time with the March-year-end majors' June 2026 filings, will add some incremental visibility. The rules target shareholder-governance agreements, share-disposal agreements, and debt covenants rather than routine licence economics, so the practical effect is narrower than some commentary suggests, but it is one more sign of a regional market becoming more legible to outside capital.

The aggregators: consolidation in the middle of the market

If the buying and selling sides are broadening, the layer in between is doing the opposite. The dedicated royalty aggregators, the firms that defined the asset class, are consolidating, and four deals in twelve months make the pattern impossible to miss.

Ligand agreed in April 2026 to acquire XOMA Royalty for roughly $739 million plus a litigation-linked contingent value right, a 14% premium that takes the combined portfolio past 200 assets. Ligand comes into the deal with momentum, having reported 48% royalty revenue growth for 2025 in its February 2026 results and reaffirmed 2026 guidance reflecting a partial-year XOMA contribution. XOMA itself was the purest example of the small-ticket model, a book of more than a hundred royalties assembled by buying distressed biotech shells for limited cash plus contingent value rights. That model has not been disproven. It has been bought.

KKR took HealthCare Royalty Partners private in July 2025, acquiring a majority stake in a firm that has committed more than $7 billion across 110-plus products since 2006 and feeding its origination into KKR's $6.5 billion asset-based finance vehicle. The signal there is the buyer: when one of the world's largest asset-based finance franchises wants a captive royalty engine rather than a co-investment relationship, royalty origination has stopped being a niche specialty and become a feeder for a much larger credit machine.

The GHO Capital and CBC Group merger in May 2026 makes the same move in Asia, combining a London and a Singapore manager into a roughly $21 billion healthcare house, with the region's dedicated royalty platform now sitting inside it rather than competing as a standalone.

And Zymeworks is doing something stranger and more interesting, building an aggregator from the inside out. The conventional aggregator starts with capital and goes looking for royalties; Zymeworks started with one high-quality royalty, on Ziihera, and is building outward from it. In March 2026 it entered a $250 million non-recourse royalty-backed note with Royalty Pharma, pledging only 30% of the royalty with a return capped at 1.65x then 1.925x, to fund buybacks and, more tellingly, acquisitions. It then hired EcoR1's Scott Platshon as Chief Business Officer and a deal-making team, and every 2026 release now opens by describing the company's "asset and royalty aggregation strategy". It is an open test of whether an operating biotech can bootstrap itself into a diversified aggregator from a single asset, and the obvious risk is the obvious one for any single-asset story: the whole thing rests on Ziihera performing.

Read the four together and the structure of the middle of the market is clear. There is a top tier of scale platforms that can write tickets nobody else can reach, led by Royalty Pharma, which deployed $2.6 billion of cash in 2025 and grew Portfolio Receipts 16% to $3.25 billion and internalised its manager for a permanent cost-of-capital edge, with KKR-owned HCRx, Blackstone, the Ligand and XOMA combine, and the GHO and CBC platform behind it. There is a middle tier of mid-scale specialists, DRI Healthcare, which reported a $777.8 million royalty book and more than $1.25 billion of committed capital in its March 2026 full-year results, Oberland, Sagard, Pharmakon's BioPharma Credit, OMERS, NovaQuest, doing real volume in a $50 to $300 million band the scale platforms can reach down into at will. And there is a thinning tail of single-stream vehicles and specialty originators, SWK in the sub-$50 million niche, Theravance reduced to a single-asset wind-down, that is being absorbed rather than failing.

Why is the tail thinning? The mechanism is cost of capital, and it is the same force visible in the buy-side and the seller-side sections. A sub-scale fund with closed-end vintage capital and deal-by-deal investor risk cannot price against a permanent-capital balance sheet on the same asset. So it either specialises into a niche the giants ignore or it gets out-bid, and increasingly it is worth more inside a larger platform than outside one. XOMA at a 14% premium plus a litigation CVR is what that looks like in practice.

There is a real counter to the consolidation thesis, and it sits in the demand data from earlier. The Deloitte survey Royalty Pharma commissioned found 87% of biopharma executives would consider royalties for capital over the next three years. If seller demand is broadening that fast, there may be room for specialists serving sizes and structures the giants find uneconomic to chase. Scale wins the big tickets. It does not automatically win the whole market.

The macro backdrop: why the asset class held up

No account of where this market goes makes sense without the rate environment, because royalty valuation is a discounting exercise and discounting is where rates bite. A royalty is a stream of future cash flows, and its present value is those flows discounted at a rate built up from the government bond yield plus premia for credit, concentration, patent risk, and illiquidity. The 10-year Treasury sits at the bottom of every royalty valuation in the market. I set out the full discount-rate stack in the royalty bonds piece.

The naive expectation would be that the rate shock of 2022 and 2023 crushed the royalty market. As one valuation house walked through the arithmetic, a biotech discount rate moving from 12% to 15% cuts risk-adjusted net present values by anywhere from 32% to 70%, and long-dated royalties are exactly the long-duration assets that should suffer most.

The interesting fact is that it did not work out that way, and the reason is that rates hit the two sides of a royalty deal asymmetrically. Higher rates raise a buyer's cost of capital modestly. They hit the biotech seller far harder, because when rates rose, biotech equity collapsed, the IPO window shut, and venture funding fell 35% in 2022 and another 24% in 2023. A company that cannot sell equity at a reasonable price and cannot afford new debt suddenly finds a royalty sale to be the cheapest capital available.

So the market is structurally counter-cyclical to biotech equity. Demand for royalty capital rises precisely when the macro environment is worst for the alternatives, and Gibson Dunn's 2026 read is that the 2022 dip was a temporary freeze, not a structural weakness, with volume recovering to records even as rates held above 5%. Royalty demand is now embedded in how biopharma funds itself.

There is a second macro point that explains why the institutional money is interested at all. Pharmaceutical royalties are close to uncorrelated with equities and rates over the medium term, because patients take their medicines through recessions and drug prices have historically outrun inflation. For an allocator who watched stock-bond correlations turn positive in 2022, a cash-flowing asset divorced from the cycle is exactly the diversifier that is hard to find. That is the property pulling pension and insurance money in, and it survived the rate regime that punished almost everything else. The caveat is that uncorrelated is a medium-term, diversified-pool claim: a single patent cliff or clinical failure is fully idiosyncratic and can take one royalty to zero, which is one more reason scale wins.

The music and oil mirrors

There is one more way to read where this goes, which is to look sideways at the two royalty asset classes that have already turned their cash flows into rated, tradable, securitised paper. Music and oil and gas both did it. Pharma, despite a deeper capital base, mostly has not.

Music is the seductive comparison. The asset class went from David Bowie's 1997 securitisation to a mainstream rated market in under three decades, with Concord's $1.8 billion Apollo-anchored deal rated A+ and a record $4.4 billion of music-backed debt raised by September 2025. What makes it work is diversification across a million-plus songs, where no single track sinks the structure. That is precisely the property a pharma royalty pool struggles to replicate, because drug revenue is lumpier and exposed to patent and clinical events with no equivalent in a back catalog.

Oil and gas is the more honest mirror. Producers have securitised proved developed reserves since 2019, and Diversified Energy reached a Fitch BBB rating only by pledging 85% of production for ten years and running rolling hedges, while Raisa hit investment grade by pooling more than 3,000 wellbores. The lesson is blunt: you reach an investment-grade rating on volatile cash flows only by stacking heavy structural protection on top. Patent cliffs make a drug royalty look more like a depleting well than a song, which points toward the oil model rather than the music one.

Pharma has run this experiment before, and it shaped the whole market's caution. I traced the full history in the royalty bonds piece, so the one-line version will do: the canonical single-asset securitisation collapsed almost immediately when its only drug stumbled, and twenty-five years later the market still reads concentrated pharma royalty paper with that memory intact. The deeper reason a true diversified pharma royalty ABS has not reopened at scale is that the dominant holders borrow more cheaply at the fund level than any rated tranche would clear, so they have no reason to sell into a competing instrument. That is the same cost-of-capital edge that lets the scale platforms roll up the tail, seen from another angle.

Where this is heading

Pull the layers together and a few things look likely through 2026 and 2027, held loosely and stated as expectations rather than forecasts.

The capital keeps coming, and it keeps arriving through large balance sheets rather than new specialists. The pattern of the last two years is unambiguous on this: KKR bought HCRx rather than raising a royalty fund, RA Capital bolted a royalty arm onto an equity firm, GHO absorbed the region's Asia platform, Blackstone runs royalties inside a diversified life-sciences fund, and the largest pensions originate in-house. Rising interest enables entry, but the entry is by diversified houses and direct-investing institutions, not by a wave of first-time pure-play funds. There is no verified pure-play first-time royalty fund of meaningful scale launched in 2024 to 2026, which is itself a data point.

The middle consolidates further. The gap between a permanent-capital balance sheet and a closed-end fund widens with every deal, and the natural next move is a second large asset-based finance platform, an Apollo, Ares, Blue Owl, or Brookfield, buying a mid-tier originator the way KKR bought HCRx. A deal of that shape inside twelve to eighteen months would fit the pattern; its absence would be a mild argument against it. The honest qualifier is that three deals is a small sample, and they could cluster for idiosyncratic reasons rather than a structural one.

The synthetic structure keeps taking share, and this is the most secure of the calls. It sidesteps the consent friction that gates traditional monetisations, it suits sellers who want non-dilutive capital while keeping optionality, and the demand data points hard in its direction. The likeliest way it is wrong is a rate move or a high-profile synthetic blow-up that resets risk appetite, which is never visible until it is.

And the next leg of growth is probably geographic. The China out-licensing wave is real, the NewCo structure is the clean legal bridge that lets those assets become royalties, and the largest aggregator has now put a senior person on the ground in Hong Kong to chase it. The first true China-origin synthetic royalty is the deal to watch, because it would confirm that the asset class has found its next frontier rather than just its next large counterparty.

If the overall thesis is wrong, the evidence will be specific. Announced 2026 volume falling back below the $7 billion five-year average would weaken the growth story. Royalty Pharma's share dropping well under 30% as others scale would weaken the concentration story. A credible pure-play first-time fund closing $500 million or more would falsify the no-new-entrants claim. And a US-China decoupling event that closes the NewCo channel would shut the Asian frontier before it opens. Any one of those is worth a follow-up.

The verdict

The pharmaceutical royalty market in May 2026 is bigger, more crowded, and more global than it has ever been, and it is consolidating in the middle even as it broadens at both ends.

The buying side has filled with insurance capital, asset-based finance platforms, and direct-investing pensions. The selling side has widened from biotechs and universities to include Big Pharma using royalties to manage its own balance sheet. The assets are starting to come out of Asia as well as the US and Europe. And the dedicated aggregators that defined the market are being rolled up, taken private, or rebuilt from the inside, because permanent capital prices royalty risk more cheaply than vintage fund capital can.

The common thread running through every layer is cost of capital. It is why insurance and pension money is crowding in, why Big Pharma can afford to sell, why the scale platforms can out-bid the tail, and why the securitisation market that music and oil built stays closed in pharma. Whoever funds most cheaply wins the asset, and right now that is the largest balance sheets.

The macro environment reinforces all of it rather than threatening it. The rate shock that was supposed to crush the asset class instead fed it, because high rates hurt the biotech sellers more than the royalty buyers, and the uncorrelated cash flow is exactly what allocators have been hunting since stock-bond correlations turned.

Taking stock in May 2026, the direction is clear and the magnitude is not. The market is growing, concentrating, and globalising at the same time, and the open questions are how far the consolidation runs, whether the long tail survives by specialising, and whether the China wave becomes the next real engine of supply. The next clutch of deals, and the first genuine China-origin royalty, will answer more of it than any forecast can.

This article reflects publicly available information as of May 2026. It does not constitute investment, legal, or financial advice. Transaction details are drawn from SEC filings, company press releases, and published market commentary. The author is not a lawyer or financial adviser.